Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Asthma Control Study 2011

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: February 16, 2011
Last updated: October 24, 2011
Last verified: October 2011
Asthma control study 2011

Asthma Control Level

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Asthma Control Study 2011

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Asthma control level [ Time Frame: 2 times ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Routine Therapeutical habits in control maintenance [ Time Frame: 2 time ] [ Designated as safety issue: No ]

Enrollment: 1524
Study Start Date: February 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Asthmatic patients above 18 y

Inclusion Criteria:

  • Asthmatic patients above 18 y

Exclusion Criteria:

  • COPD
  • pulmonary cancer
  • pulmonary tuberculosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01298739

  Show 53 Study Locations
Sponsors and Collaborators
Principal Investigator: György Losonczy, MD PHD Semmelweis University Budapest Pulmonology Clinic
  More Information

Responsible Party: AstraZeneca Identifier: NCT01298739     History of Changes
Other Study ID Numbers: NIS-RHU-XXX-2011/1 
Study First Received: February 16, 2011
Last Updated: October 24, 2011
Health Authority: Hungary: National Institute of Pharmacy

Keywords provided by AstraZeneca:
asthma control level , ACQ

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on December 09, 2016